Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Wire Texas.
Press releases published on June 12, 2025
Spring Bio Solution führt NCE Grid zur Entschlüsselung von Paragraph-IV-Anmeldungen und First-to-File-Möglichkeiten ein
GlobeNewswire
·
June 12, 2025
SOMERSET, New Jersey, June 12, 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution, ein weltweit führender Anbieter von Vergleichsprodukten und Zubehör für klinische Studien, hat NCE Grid eingeführt – die weltweit erste kostenlose NCE-1-Informationsplattform, die …
Spring Bio Solution lance NCE Grid pour décoder les dépôts Para IV et les opportunités de premier déposant
GlobeNewswire
·
June 12, 2025
SOMERSET, New Jersey, 12 juin 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution, l’un des leaders mondiaux de l’approvisionnement en comparateurs et en matériel pour essais cliniques, a lancé NCE Grid, une plateforme d’informations NCE-1 gratuite. Conçue pour …
Spring Bio Solution Meluncurkan NCE Grid untuk Mendekode Peluang Pengajuan Para IV dan First-to-File
GlobeNewswire
·
June 12, 2025
SOMERSET, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution, pemimpin global dalam pengadaan obat pembanding dan perlengkapan uji klinis, telah meluncurkan NCE Grid, platform kecerdasan NCE-1 gratis pertama di dunia - yang dibuat untuk mendekode, …
スプリング・バイオ・ソリューション (Spring Bio Solution) 、パラグラフIV証明書を伴う申請 (Para IV Filing) およびファースト・トゥ・ファイル機会を解析するNCEグリッド (NCE Grid) を発表
GlobeNewswire
·
June 12, 2025
ニュージャージー州サマセット発, June 12, 2025 (GLOBE NEWSWIRE) -- コンパレータ調達および治験薬供給のグローバルリーダーであるスプリング・バイオ・ソリューションは、世界初の無料NCE-1インテリジェンス・プラットフォームであり、パラグラフIVおよびNCE-1の機会をリアルタイムで解析・集約・可視化することを目的として構築されたNCEグリッドを発表した。 これまで、NCE独占期間の満了およびパラグラフIV …
Spring Bio Solution, 패러그래프 IV 준비와 최초 출원 가능성 해석해주는 NCE Grid 플랫폼 선보여
GlobeNewswire
·
June 12, 2025
미국 뉴저지주 서머싯, June 12, 2025 (GLOBE NEWSWIRE) -- 대조약 공급 및 임상시험 용품 분야의 글로벌 선도 기업 Spring Bio Solution이 세계 최초로 무료 NCE-1 인텔리전스 플랫폼 NCE Grid를 선보였다. 이 플랫폼은 패러그래프 IV 준비와 NCE-1 가능성을 실시간으로 해석하고, 중앙화 및 시각화하기 위해 설계되었다. 지금까지 NCE 독점권 만료일 추적과 패러그래프 IV 증명서 제출은 중앙화된 솔루션이 없어 …
Spring Bio Solution Melancarkan NCE Grid untuk Menyahkod Pemfailan Para IV dan Peluang Pemfail Pertama
GlobeNewswire
·
June 12, 2025
SOMERSET, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution, peneraju global dalam penyumberan komparator dan bekalan percubaan klinikal telah melancarkan NCE Grid, platform risikan NCE-1 percuma pertama di dunia—dibangunkan untuk menyahkod, …
Spring Bio Solution 推出 NCE Grid，用于分析 Para IV 申请和“首先申请”机会
GlobeNewswire
·
June 12, 2025
萨默塞特，新泽西州, June 12, 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution 是对照药采购和临床试验用品领域的全球领导者，近日推出了 NCE Grid，这是全球首个免费的 NCE-1（新化学实体批准日期满48个月后的第一天，通常被称为“首仿日”）情报平台，用于实时分析及实现 Para IV（第IV段声明专利挑战） 和 NCE-1 机会的集中化和可视化。 在这之前，追踪 NCE 独占期到期情况和 Para IV …
Spring Bio Solution เปิดตัว NCE Grid เพื่อถอดรหัสการยื่นเอกสาร Para IV และโอกาสในการยื่นคำขอครั้งแรก
GlobeNewswire
·
June 12, 2025
ซอเมอร์เซ็ต นิวเจอร์ซีย์, June 12, 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution ผู้นำระดับโลกในด้านการจัดหาตัวเปรียบเทียบและอุปกรณ์การทดลองทางคลินิก ได้เปิดตัว NCE Grid แพลตฟอร์มปัญญาประดิษฐ์ NCE-1 ฟรีแห่งแรกของโลกที่สร้างขึ้นเพื่อถอดรหัส การรวมข้อมูล …
Spring Bio Solution 推出 NCE Grid，用於分析 Para IV 申請和「首先申請」機會
GlobeNewswire
·
June 12, 2025
薩默塞特，新澤西州, June 12, 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution 是對照藥採購和臨床試驗用品領域的全球領導者，近日推出了 NCE Grid，這是全球首個免費的 NCE-1 情報平台，用於即時分析及實現 Para IV 和 NCE-1 機會的集中化和可視化。 到目前為止，追蹤 NCE 專有權到期情況和 Paragraph IV 申請一直是分散且繁瑣的人手程序，缺乏集中式解決方案。 …
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
GlobeNewswire
·
June 12, 2025
PRINCETON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced new preclinical data on the use of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) in a mouse …
Counslr Launches in Texas to Increase Access to Mental Health Support for Staff and Students
GlobeNewswire
·
June 12, 2025
NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Counslr, a leading B2B mental health and wellness platform, announced today that it has expanded its footprint into the State of Texas starting with a partnership with Colorado Independent School District (ISD) …
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
GlobeNewswire
·
June 12, 2025
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of full PoNSTEP study results expanded upon top line data …
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström…
GlobeNewswire
·
June 12, 2025
Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses Data reinforces …
American Journal of Respiratory and Critical Care Medicine Publishes Landmark Data on AeroPace® System's Breakthrough Results in Ventilator Weaning
GlobeNewswire
·
June 12, 2025
EXTON, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Lungpacer Medical, Inc., a pioneering medical device company focused on neurostimulation therapies for critical care patients, today announced the publication of pivotal clinical trial results in the American …
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
GlobeNewswire
·
June 12, 2025
– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy- …
I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire
·
June 12, 2025
ROCKVILLE, Md., June 12, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that on …
Catheter Precision (VTAK) Reports Key Progress for the LockeT Product
GlobeNewswire
·
June 12, 2025
FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that LockeT …
BioNTech kündigt strategische Transaktion zur Übernahme von CureVac im Rahmen eines öffentlichen Umtauschangebots an
GlobeNewswire
·
June 12, 2025
Die geplante Übernahme soll die Forschung, Entwicklung, Herstellung und Kommerzialisierung von mRNA-basierten Krebsimmuntherapie-Kandidaten stärken und ist ein weiterer wichtiger Meilenstein in der Umsetzung von BioNTechs Onkologie-Strategie Die Übernahme …
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
GlobeNewswire
·
June 12, 2025
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its oncology strategy Acquisition of CureVac will complement …
New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients
GlobeNewswire
·
June 12, 2025
WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central …